Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).
Ashish SharmaFrank G HolzCarl D RegilloK Bailey FreundDavid SarrafArshad M KhananiCaroline BaumalNancy M HolekampRamin TadayoniNilesh KumarNikulaa ParachuriBaruch D Kuppermannnull nullnull nullFrancesco BandelloGiuseppe QuerquesAnat LoewensteinŞengül ÖzdekKourous RezaiKodjikian LaurentAlper BilgicPaolo LanzettaDinah ZurNicolas YannuzziGiulia CorradettiPeter KaiserAssaf HilelyDavid BoyerAleksandra RachitskayaUsha ChakravarthyMaximilian WintergerstValentina SaraoBarbara ParoliniPrithvi MruthyunjayaQuan Dong NguyenDiana DOPearse A KeaneTarek HassanJayanth SridharDavid EichenbaumDilraj GrewalMartin SplitzerPublished in: Expert opinion on biological therapy (2023)
The Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe.